SCHEMBL24028372

SCHEMBL24028372

CNC(=S)c1cccc(N)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2 P00734 1/20 0.47
PLG P00747 1/20 0.47
PRSS1 P07477 1/20 0.47
PRSS2 P07478 1/20 0.47
PRSS3 P35030 1/20 0.47
PBRM1 Q86U86 1/20 0.46
GAA P10253 3/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
RAB9A P51151 1/20 0.44
LMNA P02545 2/20 0.43
NPC1 O15118 1/20 0.43
MITF O75030 1/20 0.43
POLB P06746 1/20 0.43
ALDH1A1 P00352 5/20 0.42
KDM4E B2RXH2 1/20 0.42
CYP3A4 P08684 1/20 0.42
CASP1 P29466 1/20 0.42
RECQL P46063 1/20 0.42
MAPT P10636 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7501911 0.78 ALDH1A1 (0.50) MEN1KMT2ARAB9ALMNANPC1
SCHEMBL29944867 0.76 HDAC8 (0.63) F2PLGPRSS1PRSS2PRSS3
SCHEMBL520073 0.76 HDAC8 (0.63) F2PLGPRSS1PRSS2PRSS3
SCHEMBL25581862 0.76 F2 (0.47) F2PLGPRSS1PRSS2PRSS3
SCHEMBL11666931 0.76 MEN1 (0.56) PBRM1GAAMEN1KMT2ARAB9A
SCHEMBL11234413 0.74 PBRM1 (0.57) F2PLGPRSS1PRSS2PRSS3
SCHEMBL31650871 0.74 F2 (0.59) F2PLGPRSS1PRSS2PRSS3
SCHEMBL1091579 0.74 F2 (0.59) F2PLGPRSS1PRSS2PRSS3
SCHEMBL1379363 0.73 NPC1 (0.52) GAAMEN1KMT2ARAB9ALMNA
SCHEMBL23197915 0.73 KAT6A (0.42) GAALMNAALDH1A1KDM4ECYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230174507-A1 IMIDAZOLE 3-OXIDE DERIVATIVE BASED ACSS2 INHIBITORS AND METHODS OF USE THEREOF METABOMED LTD. (IL) 2023-06-08 US disclosed
US-20230174507-A1 IMIDAZOLE 3-OXIDE DERIVATIVE BASED ACSS2 INHIBITORS AND METHODS OF USE THEREOF METABOMED LTD. (IL) 2023-06-08 US disclosed
WO-2021229571-A1 IMIDAZOLE 3-OXIDE DERIVATIVE BASED ACSS2 INHIBITORS AND METHODS OF USE THEREOF METABOMED LTD (IL) 2021-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174507-A1 IMIDAZOLE 3-OXIDE DERIVATIVE BASED ACSS2 INHIBITORS AND METHODS OF USE THEREOF ACSS2, ADSS2, GLS2 F2 3418/4885PLG 3652/4885PRSS1 62/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.